Argentina
Argentina
Search
Spain
Our facility in Spain is home to Regulatory Affairs Services and two technology hubs. Explore career opportunities in Spain or our 170 global locations.
Singapore
Singapore
Clinical Studies
Clinical Studies
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
Human Health Innovation
Human Health Innovation
Science & Innovation
Science & Innovation
Fostering Science
Fostering Science
Board of Managing Directors
Board of Managing Directors Boehringer Ingelheim
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
Do you take periodontal disease in dogs seriously? We do!
Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
Corporate Strategy & Consulting
Corporate Strategy & Consulting
People, Finance & Organization
People, Finance & Organization
Information Technology
IT
Get in touch
Get in touch
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine